secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zai Lab Ltd (ZLAB)
CIK:        0001704292
Form:       8-K
Filed at:   2023-01-05T23:59:59+00:00
Accession:  0001628280-23-000450
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zai Lab partner Novocure's LUNAR study meets primary overall survival endpoint in stage 4 NSCLC
--------------------------------------------------------------------------------

- LUNAR study showed statistically significant and clinically meaningful improvement in overall survival vs standard therapies alone.
- TTFields + immune checkpoint inhibitors demonstrated significant OS benefit; positive trend with TTFields + docetaxel.
- Zai Lab has exclusive license to develop and commercialize TTFields in mainland China, Hong Kong, Macau, and Taiwan.
- Novocure plans to file PMA with FDA and CE Mark in EU in H2 2023; full results at future medical congress.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1704292/000162828023000450/0001628280-23-000450-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1704292/000162828023000450/zlab-20230105.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-000450

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer